6-Mercaptopurine(6-MP)Monohydrate

Molecular Weight (MW)	170.19
Formula	C5H6N4OS
CAS No.	6112-76-1
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 100 mg/mL (587.6 mM)
Water: <1 mg/mL
Ethanol:<1 mg/mL
Other info	Chemical Name: 1,7-dihydro-6H-purine-6-thione hydrate InChi Key: WFFQYWAAEWLHJC-UHFFFAOYSA-N InChi Code: InChI=1S/C5H4N4S.H2O/c10-5-3-4(7-1-6-3)8-2-9-5;/h1-2H,(H2,6,7,8,9,10);1H2 SMILES Code: S=C1NC=NC2=C1NC=N2.[H]O[H]
Synonyms	6-MP; Mercaptopurine; NSC 755; 6 MP; NSC755; 6MP; NSC-755; 6-Mercaptopurine hydrate

Molecular Weight (MW)

170.19

Formula

C5H6N4OS

CAS No.

6112-76-1

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 100 mg/mL (587.6 mM)

Water: <1 mg/mL

Ethanol:<1 mg/mL

Other info

Chemical Name: 1,7-dihydro-6H-purine-6-thione hydrate

InChi Key: WFFQYWAAEWLHJC-UHFFFAOYSA-N

InChi Code: InChI=1S/C5H4N4S.H2O/c10-5-3-4(7-1-6-3)8-2-9-5;/h1-2H,(H2,6,7,8,9,10);1H2

SMILES Code: S=C1NC=NC2=C1NC=N2.[H]O[H]

Synonyms

6-MP; Mercaptopurine; NSC 755; 6 MP; NSC755; 6MP; NSC-755; 6-Mercaptopurine hydrate

In Vitro	In vitro activity: Mercaptopurine is widely used to treat malignancies, rheumatic diseases, dermatologic conditions, inflammatory bowel disease, and solid organ transplant rejection. Mercaptopurine inhibits purine nucleotide synthesis and metabolism by inhibiting an enzyme called Phosphoribosyl pyrophosphate amidotransferase (PRPP Amidotransferase). PRPP Amidotransferase is the rate limiting enzyme of purine synthesis. It alters the synthesis and function of RNA and DNA. Mercaptopurine interferes with nucleotide interconversion and glycoprotein synthesis.
In Vivo	In the fetal telencephalons of the 6-Mercaptopurine hydrate (6-MP)-treated group, the S phase cell population increases at 36 and 48 h and returns to the control level at 72 h after treatment. The G2/M phase cell population begins to increase at 24 h, peaks at 36 h, decreases at 48 h, and finally returnes to the control level at 72 h. On the other hand, the sub-G1 phase cell population (apoptotic cells) begins to increase at 36 h, peaks at 48 h, and then decreases at 72 h.
Animal model	Rats
Formulation & Dosage	Around thirteen-week-old pregnant rats are used in this study. The animals are housed individually in wire-mesh cages in an air-conditioned room (temperature, 23±3°C; humidity, 50±20%; ventilation, 10 times/hour; lighting, 12 h light to12 h dark cycle) and are given pelleted diet and water ad libitum. In the experiment, fifteen pregnant rats are injected i.p. with 50 mg/kg 6-Mercaptopurine hydrate (6-MP) on E13, and three dams each are sacrificed by exsanguination from the abdominal aorta under ether anesthesia at 12, 24, 36, 48, and 72 h. Fetuses are collected from each dam by Caesarean section. As controls, fifteen pregnant rats are injected i.p. with 2.0% methylcellulose solution in distilled water at E13, and three dams are sacrificed at each of the same time-points
References	Eur J Clin Pharmacol. 2008 Aug;64(8):753-67; Am J Hum Genet. 1980 Sep;32(5):651-62.

In Vitro

In vitro activity: Mercaptopurine is widely used to treat malignancies, rheumatic diseases, dermatologic conditions, inflammatory bowel disease, and solid organ transplant rejection. Mercaptopurine inhibits purine nucleotide synthesis and metabolism by inhibiting an enzyme called Phosphoribosyl pyrophosphate amidotransferase (PRPP Amidotransferase). PRPP Amidotransferase is the rate limiting enzyme of purine synthesis. It alters the synthesis and function of RNA and DNA. Mercaptopurine interferes with nucleotide interconversion and glycoprotein synthesis.

In Vivo

In the fetal telencephalons of the 6-Mercaptopurine hydrate (6-MP)-treated group, the S phase cell population increases at 36 and 48 h and returns to the control level at 72 h after treatment. The G2/M phase cell population begins to increase at 24 h, peaks at 36 h, decreases at 48 h, and finally returnes to the control level at 72 h. On the other hand, the sub-G1 phase cell population (apoptotic cells) begins to increase at 36 h, peaks at 48 h, and then decreases at 72 h.

Animal model

Rats

Formulation & Dosage

Around thirteen-week-old pregnant rats are used in this study. The animals are housed individually in wire-mesh cages in an air-conditioned room (temperature, 23±3°C; humidity, 50±20%; ventilation, 10 times/hour; lighting, 12 h light to12 h dark cycle) and are given pelleted diet and water ad libitum. In the experiment, fifteen pregnant rats are injected i.p. with 50 mg/kg 6-Mercaptopurine hydrate (6-MP) on E13, and three dams each are sacrificed by exsanguination from the abdominal aorta under ether anesthesia at 12, 24, 36, 48, and 72 h. Fetuses are collected from each dam by Caesarean section. As controls, fifteen pregnant rats are injected i.p. with 2.0% methylcellulose solution in distilled water at E13, and three dams are sacrificed at each of the same time-points

References

Eur J Clin Pharmacol. 2008 Aug;64(8):753-67; Am J Hum Genet. 1980 Sep;32(5):651-62.

CAS NO:	6112-76-1
规格:	≥98%

包装	价格(元)
500mg	电议
1g	电议
2g	电议
5g	电议
10g	电议
50g	电议